---
---

# 42 U.S.C., USLM ref /us/usc/t42/s247d–5a

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schII/ptB/m__us_usc_t42_s247d–5.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schII/ptB/m__us_usc_t42_s247d–6.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs247d%E2%80%935a)

## § 247d–5a. Identification of clinically susceptible concentrations of antimicrobials

    (a) __Definition__ 

        In this section, the term “clinically susceptible concentrations” means specific values which characterize bacteria as clinically susceptible, intermediate, or resistant to the drug (or drugs) tested.

    (b) __Identification__ 

        The Secretary of Health and Human Services (referred to in this section as the “Secretary”), through the Commissioner of Food and Drugs, shall identify (where such information is reasonably available) and periodically update clinically susceptible concentrations.

    (c) __Public availability__ 

        The Secretary, through the Commissioner of Food and Drugs, shall make such clinically susceptible concentrations publicly available, such as by posting on the Internet, not later than 30 days after the date of identification and any update under this section.

    (d) __Effect__ 

        Nothing in this section shall be construed to restrict, in any manner, the prescribing of antibiotics by physicians, or to limit the practice of medicine, including for diseases such as Lyme and tick-borne diseases.

([Pub. L. 110–85, title XI, § 1111][/us/pl/110/85/s1111], Sept. 27, 2007, [121 Stat. 975][/us/stat/121/975].)

 __Codification__ 

    Section was enacted as part of the Food and Drug Administration Amendments Act of 2007, and not as part of the Public Health Service Act which comprises this chapter.

----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schII/ptB/m__us_usc_t42_s247d–5.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schII/ptB/m__us_usc_t42_s247d–6.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs247d%E2%80%935a)

----------
----------

[/us/pl/110/85/s1111]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2Fs1111
[/us/stat/121/975]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F121%2F975


